Our results indicated that the TGF-βRII CAR T cells designed in this study exhibited robust activation and proliferation in response to TGF-β while maintaining moderate levels of IFN-γ and IL-2, both of which are crucial for anti-tumor immunity. The gene discussed is TGFB1; the disease is neoplasm.